INTRODUCTION
Cardiovascular (CV) disease is the leading cause of death after renal transplantation, 1 and the CV mortality rate is twice that of the general population. 2 Traditional CV risk factors such as hypertension, hyperglycemia and dyslipidemia are more prevalent in renal transplant recipients (RTRs) compared with the general population. 3 In addition, several transplant-specific factors, for example, side-effects of immunosuppressive drugs and renal allograft function, may influence the risk of CV disease. 3 Marine n-3 polyunsaturated fatty acids (PUFAs) have been reported to exert cardio-protective metabolic effects 4 including lipid modulation, 5 reduced blood pressure, 6 impairment of artery calcification, 7 anti-inflammatory, 8 anti-arrhythmic 9 and antithrombotic effects. 10 The effects of marine n-3 PUFA intake from fish consumption or supplements have been extensively studied in non-transplant populations. 11 In renal transplantation, however, no previous observational study and only small randomized controlled trials have studied the effects of marine n-3 PUFAs on lipids and blood pressure, [12] [13] [14] [15] and no study has to our knowledge investigated associations between marine n-3 PUFAs and heart rate, plasma glucose levels or measures of arterial stiffness.
The aim of this cross-sectional study was to examine associations between plasma levels of marine n-3 PUFAs and CV risk markers in a large cohort of RTRs.
MATERIALS AND METHODS

Study design and population
This single-center study was performed at Oslo University Hospital, Rikshospitalet, which serves the Norwegian population of 5.2 million inhabitants (October 2015). Between 30 September 1999 and 13 October 2011, 2978 renal transplantations were performed in 2837 patients with end-stage renal disease. At our center, we performed an in-depth clinical investigation and biobanking of plasma samples of all RTRs at 10 weeks after transplantation. Patients not eligible for inclusion in this study were either below the age of 16 years (n = 78), transferred to local hospitals before 10 weeks after transplantation (n = 335), or suffered graft loss (n = 58) or death (n = 21) within the first 10 weeks after transplantation ( Figure 1 ). Of the eligible patients, 344 patients were not offered a clinical visit 10 weeks after transplant because of understaffing at the laboratory. Furthermore, the amount of plasma collected was inadequate for individual fatty acid determination in another 11 patients, which leaves 1990 patients included in the study. Informed consent was obtained from all patients.
Data collection and registry
Blood was sampled after a minimum of 8-h overnight fast. Routine blood samples were analyzed at a central biochemical department, and, laboratory test results were entered into a database, including plasma levels of triglycerides, plasma high-density lipoprotein (HDL) cholesterol levels, plasma low-density lipoprotein cholesterol levels and fasting plasma glucose (fPG). Other blood samples were immediately frozen and stored at -80ºC and were later on sent to The Lipid Research Center, Aalborg University Hospital, Aalborg, Denmark, for analysis of plasma phospholipid fatty acid composition by gas chromatography, as previously described. 16 In short, individual fatty acids were identified and quantified as weight percentage of total plasma phospholipid fatty acids. Marine n-3 PUFA levels were defined as the sum of plasma phospholipid levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid.
Registration of pulse wave velocity (PWV), resting heart rate (rHR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements started in 2007. From three automated oscillometric upper arm blood pressure measurements (CAS Medical Systems, Branford, CT, USA) with the patients resting in a sitting position, the average of the two last measurements was recorded. PWV and rHR were measured with the patient in the supine position using SphygmoCor version 8.0 (AtCor Medical, West Ryde, NSW, Australia) as previously described. 17 The measurements were performed at the morning of the clinical visit 10 weeks after transplant immediately after blood sampling. The patients had been instructed not to take any medication or drink coffee or tea before the measurements, as this might influence the results. We used estimated glomerular filtration rate according to the Modification of Diet in Renal Disease formula 18 as a measure of renal graft function, and fPG levels were assessed in whole blood samples using a plasma calibrated HemoCue AB B-glucose Analyzer (HemoCue, Ängelholm, Skåne, Sweden). Clinical data were retrieved from medical records and from The Norwegian Renal Registry as previously described. 16 During most of the study period, the immunosuppressive regimen consisted of methylprednisolone and basiliximab induction, followed by maintenance therapy with mycophenolate, prednisolone and a calcineurin inhibitor (either cyclosporine A or tacrolimus). 16 Before 2007, nearly all patients received cyclosporine A. The choice of calcineurin inhibitor in recent years was mainly based on recipient age and whether the patient had diabetes mellitus or not. Statins were discontinued during the first 3 months after transplantation. 16 
Statistical analysis
Demographical and clinical data at 10 weeks after transplant have previously been described in detail in this cohort. 16 Patient characteristics for selected variables across quartiles of marine n-3 PUFA levels are given in Table 1 . Differences between groups were evaluated using logistic regression for binary variables, the Mantel-Haenszel test of linear trend for other categorical data, the Kruskal-Wallis test for time in dialysis therapy and linear regression for other continuous variables.
We evaluated unadjusted, recipient age-and gender-adjusted and multivariable-adjusted associations between marine n-3 PUFA levels and CV risk markers in linear regression analysis ( Table 2 ). The table displays unstandardized regression coefficients (β-coeff.) with corresponding 95% confidence interval (CI), standardized regression coefficients, P-values and adjusted explained variance. We used Po0.10 as the main inclusion criteria of variables in the final multivariable-adjusted model. Variables included in the fully adjusted models are listed in the table legend. Candidate variables included the following: (1) Recipient-related variables recorded at the time of transplantation: recipient age and gender, atherosclerotic disease (a history of coronary artery, cerebrovascular and/ or peripheral artery disease), diabetes mellitus, smoking status (current smoker, former smoker or life-long non-smoker), first or previous renal transplantation, preemptive transplantation (no previous renal transplantation or dialysis therapy) and time in dialysis therapy. In addition, donor age and type (living or deceased) as well as human leukocyte antigen DR mismatches between donor and recipient were evaluated. (2) Variables recorded at 10 weeks after transplant: Number of anti-hypertensive drugs, calcineurin inhibitor used (tacrolimus or cyclosporine A), body mass index, albumin, estimated glomerular filtration rate and marine n-3 PUFA levels.
Time in dialysis therapy was logarithmically transformed to obtain normal distribution. There were complete data on all candidate variables in 99.3% of patients.
We evaluated associations between EPA and DHA levels and CV risk markers using multivariable linear regression and univariate linear regression. EPA levels were logarithmically transformed to obtain normal distribution. As EPA and DHA consumption are derived from the same sources, associations between EPA and DHA levels and CV risk markers were analyzed separately.
In addition, we evaluated associations between n-6 PUFA levels and the ratio of n-6 PUFA to n-3 PUFA levels and CV risk markers (Supplementary Appendix).
Finally, we used Cox proportional hazard regression to estimate ageand gender-adjusted CV mortality hazard ratios (HRs) for CV risk markers and evaluate the impact of these markers on multivariable-adjusted associations between marine n-3 PUFA levels and CV mortality, as described in the Supplementary Appendix. PASW Statistics version 17.0 (IBM, New York, NY, USA) and STATA version 13.0 (Stata Corp., College Station, TX, USA) were used for the statistical analysis.
The study was approved by the Regional Committees for Medical and Health Research Ethics in Norway and was performed in accordance with the Declaration of Helsinki (ClinicalTrials.gov number NCT02017990).
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Routine blood samples, n=1990 Fasting plasma glucose, n= 1637 Resting heart rate, blood pressure and pulse wave velocity, n=741 Figure 1 . Inclusion of patients. Abbreviations: CI, confidence intervals; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Marine n-3 polyunsaturated fatty acid level was defined as the sum of plasma phospholipid levels of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid in weight percentage of total plasma phospholipids. Associations between marine n-3 polyunsaturated fatty acid level and cardiovascular risk markers were estimated using univariate, recipient age-and gender-adjusted and multivariable linear regression analysis, estimating unadjusted and adjusted associations between marine n-3 polyunsaturated fatty acid levels and cardiovascular risk markers. In addition to adjusted explained variance (R
2
) for the final model, unstandardized regression coefficients (Unstd. β-coeff.) with corresponding 95% CIs, standardized regression coefficients (Std. β-coeff.) and P-values are shown. In addition to marine n-3 polyunsaturated fatty acid levels, the following variables were included in the fully adjusted multivariable models (P o0. Table 1 . Patients with high marine n-3 PUFA levels were older, had lower n-6 PUFA levels and lower prevalence of smoking and diabetes mellitus. Adjusted for recipient age and diabetes mellitus, other associations with marine n-3 PUFA levels were nonsignificant. Table 2 shows unadjusted and adjusted associations between marine n-3 PUFA levels and CV risk markers. Marine n-3 PUFA levels were negatively associated with rHR, fPG and triglycerides and positively associated with HDL cholesterol in unadjusted, age-and gender-adjusted and multivariable linear regression analyses (Table 2) .
RESULTS
Patient characteristics are presented in
We also assessed associations with CV risk markers for EPA and DHA levels in separate multivariable linear regression models. Both were negatively associated with rHR, fPG and plasma triglyceride levels (Table 3 ). In contrast, EPA levels were positively associated and DHA levels negatively associated with HDL cholesterol, after adjustment for multiple covariates (Table 3) . In comparison, univariate linear regression analysis showed a significant positive association with HDL cholesterol with EPA levels, whereas DHA levels were not associated with HDL cholesterol levels (unstandardized β − 0.226, standardized β − 0.019, P = 0.41).
Using age-and gender-adjusted Cox proportional hazard regression, we found a tendency toward higher CV mortality risk with plasma triglyceride levels (per 50 mg/dl increase; adjusted HR 1.07, 95% CI 0.98-1.16) and rHR (per 5 b.p.m. increase; adjusted HR 1.09, 95% CI 0.99-1.20) but not for fPG or HDL cholesterol. In multivariable Cox proportional hazard regression analysis, adjusting for variables likely to confound associations between marine n-3 PUFA levels and CV risk, there was a 10% lower risk of death because of CV disease per 1.0 wt% increase in marine n-3 PUFA levels (multivariable-adjusted HR 0.90, 95% CI 0.82-0.98). The association was weakened by 1% after additional adjustment for triglycerides (multivariable-adjusted HR 0.91) and 2% when adjusting for the impact of rHR.
DISCUSSION
The major finding in this study was that marine n-3 PUFA levels were negatively associated with rHR, fPG and plasma triglycerides but positively associated with plasma HDL cholesterol. EPA levels were positively associated, whereas, in contrast, the levels of DHA were negatively associated with HDL cholesterol in multivariable linear regression analysis.
Plasma lipids A triglyceride-lowering effect from marine n-3 PUFA intake has been repeatedly shown in diverse patient populations 4 including patients with end-stage renal disease 19 and RTRs. [12] [13] [14] Consistent with these reports, we found a negative association with triglycerides for EPA, DHA and marine n-3 PUFA levels. In the Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS), addition of 1.8 g of purified EPA to statin therapy significantly lowered triglycerides and reduced the incidence of major CV events in dyslipidemic patients. 20 This is of particular interest in RTRs, who frequently have dyslipidemia and suffer high CV morbidity and mortality rates. 2 Uremic dyslipidemia is characterized by high triglycerides and low HDL cholesterol. 21 Consistent with the findings in this study, a statistically significant small increase in HDL cholesterol of 2.2 mg/ dl was found in a meta-analysis of interventional studies on the effects of marine n-3 PUFA supplementation for a minimum of 3 months following renal transplantation. 12 In multivariable linear regression, levels of EPA were positively and DHA negatively associated with plasma HDL cholesterol levels. A similar finding has previously been shown in an epidemiological study in a Norwegian cohort. 22 However, this finding is not consistent with reports from head-to-head comparative studies, where DHA treatment more efficiently increased HDL cholesterol than EPA treatment. 23 In univariate linear regression analysis, DHA levels were not significantly associated with HDL cholesterol, suggesting a neutral rather than ) for the final model, unstandardized regression coefficients (Unstd. β-coeff.), 95% CIs, standardized regression coefficients (Std. β-coeff.) and P-values are shown. In addition to either eicosapentaenoic or docosahexaenoic acid levels, the following variables were included in the fully adjusted multivariable models (Po0. a negative effect. We have no good explanation to the unexpected divergent associations with HDL cholesterol between EPA and DHA levels in this study.
We found no association between marine n-3 PUFA, EPA or DHA levels and plasma low-density lipoprotein cholesterol levels, consistent with previous reports in RTRs. [12] [13] [14] Plasma glucose Despite the higher age group, patients with high marine n-3 PUFA levels had less often diabetes mellitus in our cohort. Epidemiological studies from different regions with diverse dietary habits report equivocal and inconsistent results, with both positive, neutral and negative associations between fish consumption and the risk of developing type 2 diabetes mellitus. 24 Reports from European studies indicate that consumption of lean fish does not lower the risk of developing type 2 diabetes mellitus, as opposed to consumption of fatty fish. 25 A large American study reported a higher risk of developing type 2 diabetes mellitus with higher consumption of fish and seafood, whereas opposite associations have been found in Chinese and Japanese populations. [26] [27] [28] Consumption of marine n-3 PUFAs in our cohort was about five times higher than in the American cohort, 26, 29 and other dietary habits like sugar consumption also likely differ between the cohorts and could influence the results. 30 Meta-analysis of prospective studies that used fatty acid analysis for determination of fish consumption showed a nonsignificant negative tendency toward lower risk of developing type 2 diabetes mellitus with higher levels of marine n-3 PUFAs. 24 Also, this meta-analysis did not include a recent large Nordic study, which found a significant negative association between plasma marine n-3 PUFA levels and the risk of incident type 2 diabetes, even after adjustment for diet and lifestyle factors. 31 We found a negative association between marine n-3 PUFA levels and fPG in non-diabetic RTRs. Hepatic glycogenolysis as well as hepatic and renal gluconeogenesis are key determinants of fPG in the morning. These processes are regulated by substrate availability (gluconeogenesis) and hormonal effects (insulin and glucagon). 32, 33 One could speculate that marine n-3 PUFAs in some way affect one or more of these pathways. Mechanistically, reports from animal models and humans suggest that marine n-3 PUFAs might improve glucose homeostasis through maintenance of insulin growth factor 1 secretion, improving peripheral insulin responses, increased glucagon-like peptide 1 release, increasing insulin secretion from pancreatic beta and increased adiponectin levels, preventing insulin resistance linked to obesity. 34 There is no evidence for improved glycemic control or reduced CV morbidity or mortality after marine n-3 PUFA supplementation in non-transplant patients with type 2 diabetes mellitus or impaired glucose tolerance. 34, 35 However, the effects of marine n-3 PUFAs have not been studied in patients with posttransplantation diabetes mellitus.
In non-diabetic populations, the effects of marine n-3 PUFA supplementation on insulin secretion and sensitivity differ between patient populations. [36] [37] [38] Interventional studies with adequate sample size and follow-up time are needed to clarify whether high intake of marine n-3 PUFAs might improve glucose homeostasis in organ transplant recipients.
rHR, blood pressure and pulse wave velocity Marine n-3 PUFA intake is found to reduce rHR and increase heart rate variability in several patient populations 9 including cardiac transplant recipients. 39 We have previously reported a negative association between marine n-3 PUFA levels and CV mortality risk in this cohort. 16 The risk of sudden cardiac death was particularly low in patients with high compared with low marine n-3 PUFA levels, 16 and a similar association has also been shown in patients with end-stage renal disease. 40 Consistently, we found a negative association between marine n-3 PUFA levels and rHR, which might infer a reduced risk of CV disease. Uremic autonomic neuropathy is very frequent in end-stage renal disease patients, which partly may help explain the high incidence of SCD. 40 Normalization of renal function by renal transplantation ameliorates or reverses autonomic dysfunction within the first 3-6 months after transplantation. 41 In this study, measurements of rHR were performed at 10 weeks after transplant, by which time autonomic dysfunction still might inhibit beneficial effects of marine n-3 PUFAs on autonomic function. Both EPA and DHA make cardiomyocytes less excitable through different effects on cardiac ion channels, 39 which also contribute to lower rHR and increase heart rate variability. 9 In this cohort, levels of EPA were more strongly associated with rHR than DHA. Purified EPA supplementation in the JELIS trial did not significantly lower the incidence of SCD, 20 but this might be due to the high background consumption of marine fatty acids in a Japanese population. 42 In contrast, low-dose combined EPA and DHA supplementation in a large Italian randomized controlled trial significantly lowered the risk of SCD. 43 Marine n-3 PUFA intake has also been reported to lower both SBP and DBP. 6, 44 A meta-analysis of randomized controlled trials in RTRs reported a minor but statistically significant effect on DBP and a trend toward lower SBP after marine n-3 PUFA supplementation. 12 We failed to find any significant associations between marine n-3 PUFA levels and blood pressure in this study. However, nearly all patients received anti-hypertensive therapy, and we have only information about the number, but not the type and dose of anti-hypertensive drugs used, which obviously might be a confounding factor. Moreover, reduced blood pressure after consumption of marine n-3 PUFAs has been clearly demonstrated only in interventional studies with supplemental doses 42 g/ day, 44 which is considerably higher than the amount of marine n-3 PUFAs normally obtained through the diet, even in a Norwegian cohort. 22 Despite the high background consumption of fish, a marked reduction in SBP and DBP has previously been shown with high-dose marine n-3 PUFA supplementation in a Norwegian cohort. 6 PWV is a measure of arterial stiffness and has been reported to be associated with an increased mortality risk in RTRs. 17 Some studies have demonstrated a preventive effect of marine n-3 PUFA supplementation on progression of arterial stiffness. 45 In this study, we found no association between marine n-3 PUFA levels and PWV. This could possibly be due to a threshold effect, as lowdose marine n-3 PUFA supplementation has not shown any effect on PWV. 46 Limited data on the use of anti-hypertensive drugs might have influenced the association between marine n-3 PUFA levels and PWV.
n-6 to n-3 PUFA ratio Levels of n-6 PUFAs were inversely associated with marine n-3 PUFA levels, negatively associated with recipient age and positively associated with fPG and rHR. Associations between n-6 to n-3 PUFA ratio and CV risk markers were a little weaker than associations with absolute plasma marine n-3 PUFA levels (Supplementary Table S1 ).
The impact of CV risk markers on the associations between marine n-3 PUFA levels and CV mortality We have previously reported a negative association between marine n-3 PUFA levels and CV mortality risk in this cohort, 16 which could at least partially be explained by the findings in this study. Associations between marine n-3 PUFA levels and CV mortality risk were less pronounced after adjustment for either rHR or plasma triglyceride levels, suggesting that marine n-3 PUFAs might offer some cardio-protection after renal transplantation through effects on autonomic nervous function and very low lipoprotein synthesis and/or triglyceride clearance. 4 It should, however, be noted that the lower CV mortality risk with higher marine n-3 PUFA levels remains mostly unexplained and that neither triglycerides nor rHR was significantly associated with CV mortality risk after adjustment for age and gender.
Marine n-3 PUFAs might also lower CV mortality risk in RTRs through other cardio-protective mechanisms, including effects on inflammation or fibroblast growth factor 23 levels. 8, 47, 48 Unfortunately, we have no data to substantiate these assumptions.
Strengths and limitations
The insights provided by this study are limited by the crosssectional study design. We assumed that the plasma fatty acid composition determined at a single time point in patients who participated in the study were representative for their average fatty acid profile over time. Recent reports from Scandinavian populations have shown a strong coherence in marine n-3 PUFA levels over time and a good correlation with fish consumption. 49, 50 Unfortunately, we have no information on dietary habits and lifestyle factors like physical activity, educational level and socioeconomic status, which might be associated with marine n-3 PUFA intake. The lower prevalence of diabetes mellitus and smoking in patients with high marine n-3 PUFA levels suggest that higher marine n-3 PUFA levels could be a marker of a healthy lifestyle. Although diabetes mellitus and smoking were included as covariates in the multivariable linear regression analysis, the impact of these variables on associations between marine n-3 PUFA levels and CV risk markers might not have been fully adjusted. Any residual confounding from a healthier lifestyle associated with fish consumption cannot be ruled out. At our center, all RTRs receive regular dietary advice from a nutritionist after transplantation, including advice to eat fish at least twice a week. Possibly, high marine n-3 PUFA levels reflect good adherence to dietary advice from health personnel. Patients who were adherent to dietary advice might also be more likely to have a good drug adherence, which clearly would influence the results.
During the 10 weeks between transplantation and measurements performed in this study, the patients had gone from a uremic phase, via a post-operative phase, to a new stable posttransplantation phase. Their dietary habits might have been influenced by post-operative complications, as well as intended dietary changes motivated and made possible by the renal transplantation. Slowly progressive CV markers, for example, PWV, are not likely to respond to dietary changes on the short run. Dietary changes after the time of transplantation might therefore underestimate associations between marine n-3 PUFA levels and CV risk markers in this study.
We have data on the number, but not the type or dose of anti-hypertensive drugs, and lack data on the use of glucoselowering and anti-thrombotic drugs. The majority of patients in this Norwegian study were Caucasian; hence, results may not be applicable to other ethnic groups, and the results may not apply to regions with a lower intake of marine n-3 PUFAs.
This study also has several strengths including a well-defined and a large study population, a high inclusion rate from a single center representing an entire country and several CV risk factors included as candidate variables in the multivariable linear regression models.
In summary, plasma marine n-3 PUFA levels were associated with lower rHR, lower levels of fPG, lower plasma triglyceride levels and higher plasma HDL cholesterol levels. As both plasma triglyceride levels and rHR influenced the association between plasma marine n-3 PUFA levels and CV mortality risk, we speculate that triglyceride-lowering and anti-arrhythmic effects of marine n-3 PUFAs might prevent deaths due to CV disease after renal transplantation. Associations with plasma HDL cholesterol levels differed between plasma levels of the marine n-3 fatty acids EPA and DHA. Further clinical investigations are needed to clarify whether dietary supplementation of marine n-3 PUFAs might have clinical beneficial effects in RTRs and whether EPA and DHA exert different effects on CV risk factors in these patients.
